CHRS (Coherus Oncology) 3-Year Sortino Ratio: -0.01 (As of Jun. 24, 2026)


CHRS Coherus Oncology Inc CHRS
42 GF Score
Price $1.55
GF Value $0.77
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology 3-Year Sortino Ratio?

Coherus Oncology CHRS +5.82% 42 3-Year Sortino Ratio is -0.01 as of Jun. 24, 2026. GuruFocus rates CHRS with a GF Score™ of 42/100 and a GF Value™ of $0.77 (Significantly Overvalued). The stock has 6 warning signs investors should review.

The 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. As of today (2026-06-24), Coherus Oncology's 3-Year Sortino Ratio is -0.01.

Coherus Oncology  (NAS:CHRS) 3-Year Sortino Ratio Explanation

The 3-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past three year. It is calculated as the annualized result of the average three-year monthly excess returns divided by the standard deviation of negative returns in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.

Coherus Oncology 3-Year Sortino Ratio Related Terms

CHRS vs CNXU, LENZ, FHTX: 3-Year Sortino Ratio Comparison

For the Biotechnology subindustry, Coherus Oncology's 3-Year Sortino Ratio, along with its competitors' market caps and 3-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coherus Oncology 3-Year Sortino Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coherus Oncology's 3-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Coherus Oncology's 3-Year Sortino Ratio falls into.


CHRS
42GF Score
Coherus Oncology Inc CHRS
3-Year Sortino Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coherus Oncology 3-Year Sortino Ratio Calculation

The 3-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last three year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 3-Year Sortino Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past three year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.

Frequently Asked Questions Learn more about 3-Year Sortino Ratio →
What does a 3-Year Sortino Ratio of -0.01 mean?
Coherus Oncology (CHRS) has a 3-Year Sortino Ratio of -0.01 as of Jun. 24, 2026. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Coherus Oncology and its competitors.
Is Coherus Oncology's 3-Year Sortino Ratio too high?
Coherus Oncology's current 3-Year Sortino Ratio is -0.01. Overall, Coherus Oncology has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's 3-Year Sortino Ratio compare to CNXU and LENZ?
Coherus Oncology's 3-Year Sortino Ratio of -0.01 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Sortino Ratio for a Biotechnology company?
A good 3-Year Sortino Ratio depends on the Biotechnology industry context. However, 3-Year Sortino Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Sortino Ratio mean?
A high 3-Year Sortino Ratio can signal that a stock is expensive relative to its fundamentals. 3-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past three years. View historical data for Coherus Oncology and its competitors. Coherus Oncology's current 3-Year Sortino Ratio is -0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (CHRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.77, compared to a current price of $1.55 — trading 100.6% above its estimated fair value. The current 3-Year Sortino Ratio is -0.01. Coherus Oncology's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Sortino Ratio calculated?
3-Year Sortino Ratio is calculated from a company's financial statements. For Coherus Oncology (CHRS), the current 3-Year Sortino Ratio is -0.01 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coherus Oncology (CHRS) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of $1.55 is trading 100.6% above its estimated GF Value™ of $0.77. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for CHRS:

  • 3-Year Sortino Ratio: -0.01
  • GF Value™: $0.77 vs. price of $1.55 (100.6% above fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the CHRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges 8C5:Germany
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
42GF Score

Get the complete analysis for CHRS

3-Year Sortino Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$0.77
GF Value